 I. To assess and compare the pathologic complete response PCR rate of patients in Arm A receiving the sequence docetaxel, oxaliplatin, and capecitabine DOC followed by 5-fluorouracil 5-FU, oxaliplatin, and radiation therapy RT with patients in Arm B receiving only 5-FU, oxaliplatin and RT in patients with potentially resectable adenocarcinoma ACA of the esophagus, gastroesophageal junction GEJ, or gastric cardia. 